Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Blood (2021) 138 (23): 2337–2346.

https://doi.org/10.1182/blood.2021012206

Published: 2021

Includes: Supplemental data

Journal Articles

Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531

Erin M. Guest, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Jim Wang, Samir B. Kahwash, Amy Heerema-McKenney, Soheil Meshinchi, Alan S. Gamis

Blood (2017) 130 (7): 943–945.

https://doi.org/10.1182/blood-2017-01-762336

Published: 2017

Includes: Supplemental data

Journal Articles

Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531

Erin M. Guest, MD, Richard Aplenc, MD PhD, Lillian Sung, MD PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Samir B. Kahwash, MD, Amy Heerema-McKenney, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2014) 124 (21): 377.

https://doi.org/10.1182/blood.V124.21.377.377

Published: 2014

Journal Articles

CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children’s Oncology Group Report

Heather L Schuback, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Kristen L. Miller, BS, Samir Kahwash, MD, Amy Heerema-Mckenney, MD, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Richard Aplenc, MD PhD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2014) 124 (21): 13.

https://doi.org/10.1182/blood.V124.21.13.13

Published: 2014

Journal Articles

Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531

Keith J. August, MD MS, Richard Aplenc, MD PhD, Lillian Sung, MD PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, John T. Horan, MD MPH, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Jim Wang, MS, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2014) 124 (21): 3672.

https://doi.org/10.1182/blood.V124.21.3672.3672

Published: 2014

Journal Articles

Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group

Katherine Tarlock, MD, Todd A. Alonzo, PhD, Michael R. Loken, PhD, Robert B. Gerbing, MA, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Susana C. Raimondi, PhD, Betsy Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 2609.

https://doi.org/10.1182/blood.V122.21.2609.2609

Published: 2013

Journal Articles

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Alan S. Gamis, MD, MPH, Richard Aplenc, MD, PhD, Todd A. Alonzo, PhD, Lillian Sung, MD, PhD, Soheil Meshinchi, MD, PhD, Robert B. Gerbing, MA, Susana C. Raimondi, PhD, Betsy Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Stella M. Davies, MBBS, PhD, Patti Byron, MSN, RN, Franklin O. Smith, MD

Blood (2013) 122 (21): 355.

https://doi.org/10.1182/blood.V122.21.355.355

Published: 2013

Journal Articles

Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report

Betsy Hirsch, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Samir Kahwash, MD, Amy Heerema-McKenney, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Laura Winter, PharmD, Kathleen Glick, CCRP, Stella M. Davies, MBBS, PhD, Patti Byron, MSN, RN, Robert S. Lavey, MD, Franklin O. Smith, MD, Phoenix A. Ho, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD

Blood (2013) 122 (21): 612.

https://doi.org/10.1182/blood.V122.21.612.612

Published: 2013

Journal Articles

Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.

Blood (2012) 120 (21): 2388.

https://doi.org/10.1182/blood.V120.21.2388.2388

Published: 2012

Journal Articles

Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group

Fabiana Ostronoff, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Michael R. Loken, PhD, Laura Pardo, Richard Aplenc, MD, PhD, Lillian Sung, MD, PhD, Susana C. Raimondi, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, MSN, RN, Robert S. Lavey, MD, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2012) 120 (21): 529.

https://doi.org/10.1182/blood.V120.21.529.529

Published: 2012

Journal Articles

Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531

Michael R. Loken, PhD, Todd A. Alonzo, PhD, Laura Pardo, Robert B. Gerbing, M.A., Richard Aplenc, MD, MSCE, Lillian Sung, MD, PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, MSN, RN, Laura Fransisco, Tanya Wallas, MS, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, PhD

Blood (2011) 118 (21): 939.

https://doi.org/10.1182/blood.V118.21.939.939

Published: 2011

Journal Articles

Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,

Blood (2011) 118 (21): 3545.

https://doi.org/10.1182/blood.V118.21.3545.3545

Published: 2011

Journal Articles

Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

Alan S Gamis, MD, MPH, Todd A Alonzo, PhD, Robert B Gerbing, MS, Richard Aplenc, MD, Lillian Sung, MD, PhD, Soheil Meshinchi, MD, PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, RN, Laura Burden, Tanya Wallas, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD

Blood (2010) 116 (21): 182.

https://doi.org/10.1182/blood.V116.21.182.182

Published: 2010

Journal Articles

2008 WHO Classification of Pediatric AML.

Kara L. Davis, DO, Amy Heerema-McKenney, MD, Lisa Ma, Daniel A. Arber, MD, Gary V Dahl, MD

Blood (2010) 116 (21): 1044.

https://doi.org/10.1182/blood.V116.21.1044.1044

Published: 2010

Journal Articles

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

Lillian Sung, MD, PhD, Richard Aplenc, MD, MSCE, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Soheil Meshinchi, MD, PhD, Laura Burden, CCRP, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, BA, CCRP, Patti Byron, MSN, RN, Tanya Wallas, MS, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 1071.

https://doi.org/10.1182/blood.V116.21.1071.1071

Published: 2010

Journal Articles

High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Lillian Sung, MD, PhD, Todd A. Alonzo, PhD, Robert B. Gerbing, MS, Richard Aplenc, MD, MSCE, Soheil Meshinchi, MD, PhD, Laura Burden, CCRP, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, BA, CCRP, Patti Byron, MSN, RN, Tanya Wallas, MS, Franklin O. Smith, MD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 1072.

https://doi.org/10.1182/blood.V116.21.1072.1072

Published: 2010

Journal Articles

Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531

Michael R. Loken, PhD, Todd A. Alonzo, PhD, Laura Pardo, Robert B. Gerbing, MA, Richard Aplenc, MD, Lillian Sung, MD, PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Laura Winter, PharmD, Kathleen Glick, CCRP, Patti Byron, MSN, RN, Laura Burden, CCRP, Tanya Wallas, Stella M. Davies, MBBS, PhD, Franklin O. Smith, MD, Soheil Meshinchi, MD, PhD, Alan S. Gamis, MD, MPH

Blood (2010) 116 (21): 2740.

https://doi.org/10.1182/blood.V116.21.2740.2740

Published: 2010

NARROW

High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial

Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531

Gemtuzumab Ozogamicin (GO) in Infants with Acute Myeloid Leukemia (AML) – Combined Results from the Children’s Oncology Group (COG) Trials, AAML03P1 and AAML0531

CBFA2T3-GLIS2 Fusion Is Prevalent in Younger Patients with Acute Myeloid Leukemia and Associated with High-Risk of Relapse and Poor Outcome: A Children’s Oncology Group Report

Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531

Disease Characteristics and Prognostic Implications Of Cell Surface FLT3 Receptor (CD135) Expression In Pediatric Acute Myeloid Leukemia – A Report From Children’s Oncology Group

Gemtuzumab Ozogamicin (GO) In Children With De Novo Acute Myeloid Leukemia (AML) Improves Event-Free Survival (EFS) By Reducing Relapse Risk – Results From The Randomized Phase III Children’s Oncology Group (COG) Trial, AAML0531

Abnormalities Of 12p Are Associated With High-Risk Acute Myeloid Leukemia: A Children’s Oncology Group Report

Elevated Expression of miR-181a and miR-155 Identify Pediatric AML Patients at High Risk of Induction Failure, A Report from Children's Oncology Group.

Cryptic NUP98/NSD1 Translocations Are Highly Prevalent in FLT3/ITD-Positive Acute Myeloid Leukemia and Lead to High Rate of Induction Failure. Report From Children's Oncology Group

Multidimensional Flow Cytometry Significantly Improves Upon the Morphologic Assessment of Post-Induction Marrow Remission Status – Comparison of Morphology and Multidimensional Flow Cytometry; A Report From the Children's Oncology Group AML Protocol AAML0531

Presence of Residual Disease Detected by Multidimensional Flow Cytometry Identifies Patients with AML At High Risk of Relapse – a Report From the Children's Oncology Group,

Remission Rates In Childhood Acute Myeloid Leukemia (AML) Utilizing a Dose-Intensive Induction Regimen with or without Gemtuzumab Ozogamicin (GO): Initial Results From the Children's Oncology Group Phase III Trial, AAML0531

2008 WHO Classification of Pediatric AML.

Severe Toxicities During Pediatric Acute Myeloid Leukemia Chemotherapy: A Report From the Children's Oncology Group.

High Mortality In Extreme Hyperleukocytosis In Pediatric Acute Myeloid Leukemia: A Report From the Children's Oncology Group.

Flow Cytometric Assessment of Post Induction Response In Patients with Sub-Optimal Morphologic Response to Induction Chemotherapy- A Report From the Children's Oncology Group AML Protocol AAML0531

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only